Axsome Therapeutics(AXSM) GlobeNewswire·2025-05-01 11:00Core Viewpoint - Axsome Therapeutics is collaborating with Mental Health America to raise awareness and promote action during Mental Health Month, highlighting the importance of mental health and the impact of mental health conditions in the U.S. [1][3] Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, aiming to improve the lives of individuals with serious conditions that are difficult to treat [4][7]. - The company has an industry-leading neuroscience portfolio that includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, along with multiple late-stage development programs targeting serious neurological and psychiatric conditions affecting over 150 million people in the U.S. [7] Mental Health Statistics - Nearly 1 in 4 adults in the U.S. live with a mental illness, and more than 1 in 8 individuals aged 12 or older reported feeling depressed in the past two weeks, indicating a significant prevalence of mental health issues [3]. - Approximately 90% of individuals living with depression experience difficulties in work, home, or social activities due to their symptoms, which complicates daily life [3] Advocacy and Resources - Axsome is promoting resources for individuals and communities to take action regarding mental health, including Mental Health America's Action Guide, online screening tools, youth leadership programs, and opportunities to become mental health advocates [4][6]. - The 988 Suicide & Crisis Lifeline is highlighted as a confidential support service available 24/7, connecting individuals in crisis with trained counselors [5].